Selling, General, and Administrative Costs: Novo Nordisk A/S vs Teva Pharmaceutical Industries Limited

A Tale of Two Pharmaceutical Giants: Novo Nordisk vs. Teva

In the ever-evolving pharmaceutical industry, understanding the financial dynamics of major players is crucial. This chart offers a fascinating glimpse into the Selling, General, and Administrative (SG&A) expenses of Novo Nordisk A/S and Teva Pharmaceutical Industries Limited from 2014 to 2023. Over this period, Novo Nordisk's SG&A expenses have surged by approximately 130%, reflecting its aggressive expansion and marketing strategies. In contrast, Teva's expenses have decreased by about 31%, indicating a strategic shift towards cost optimization.

Key Insights

• Novo Nordisk: The Danish pharmaceutical giant has consistently increased its SG&A spending, peaking in 2023 with a 61.6 billion expenditure, a testament to its growth ambitions.
• Teva: The Israeli company has streamlined its operations, reducing SG&A costs to 3.5 billion in 2023, aligning with its focus on efficiency.

This comparative analysis highlights the contrasting strategies of these two industry leaders, offering valuable insights for investors and industry analysts alike.